David T. Rubin to Clinical Trials as Topic
This is a "connection" page, showing publications David T. Rubin has written about Clinical Trials as Topic.
Connection Strength
1.439
-
Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act. J Crohns Colitis. 2020 Dec 02; 14(12):1765-1768.
Score: 0.526
-
When Subjects Violate the Research Covenant: Lessons Learned from a Failed Clinical Trial of Fecal Microbiota Transplantation. Am J Gastroenterol. 2016 11; 111(11):1508-1510.
Score: 0.383
-
Performance of CT colonography in clinical trials. Gastrointest Endosc Clin N Am. 2010 Apr; 20(2):193-207.
Score: 0.251
-
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17.
Score: 0.092
-
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. J Crohns Colitis. 2023 Jul 05; 17(7):1066-1078.
Score: 0.039
-
Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflamm Bowel Dis. 2022 09 01; 28(9):1321-1331.
Score: 0.037
-
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022 03; 7(3):254-261.
Score: 0.036
-
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313.
Score: 0.031
-
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clin Gastroenterol Hepatol. 2019 08; 17(9):1673-1679.e1.
Score: 0.028
-
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
Score: 0.016